Entresto is a medication that has been proven to be effective in treating heart failure in patients with reduced ejection fraction. It is a combination of two drugs, sacubitril and valsartan, which work together to improve heart function and reduce the risk of hospitalization and death in patients with this condition.

Sacubitril is a neprilysin inhibitor, which helps to increase levels of beneficial peptides that promote vasodilation and diuresis, while valsartan is an angiotensin receptor blocker that helps to relax blood vessels and lower blood pressure. Together, these two drugs work synergistically to improve cardiac function and reduce the strain on the heart.

Entresto has been shown to significantly reduce the risk of cardiovascular death and hospitalization for heart failure compared to traditional heart failure medications. It is important to note that Entresto is not suitable for all patients, and should only be prescribed by a healthcare professional after a thorough evaluation of the patient’s medical history and current condition.

As with any medication, there may be side effects associated with Entresto, including dizziness, cough, and low blood pressure. It is important for patients to discuss any concerns or potential side effects with their healthcare provider.

Overall, Entresto is a valuable treatment option for patients with heart failure and reduced ejection fraction. It has been shown to improve outcomes and quality of life for many patients, and may be a beneficial addition to a comprehensive treatment plan for heart failure.